Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy.

[1]  Jun Luo,et al.  A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. , 2020, European urology.

[2]  Michael D. Nyquist,et al.  Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage. , 2019, The Journal of clinical investigation.

[3]  C. Drake,et al.  Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. , 2018, The Lancet. Oncology.

[4]  E. Antonarakis,et al.  Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study , 2016, The Prostate.

[5]  M. Schweizer,et al.  Targeting persistent androgen receptor signaling in castration-resistant prostate cancer , 2016, Medical Oncology.

[6]  Martin E. Gleave,et al.  Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer , 2015, Clinical Cancer Research.

[7]  Jun Luo,et al.  Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study , 2015, Science Translational Medicine.

[8]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[9]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[10]  J. Isaacs,et al.  Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer , 2010, The Prostate.

[11]  Martin J. Aryee,et al.  Androgen-induced TOP2B mediated double strand breaks and prostate cancer gene rearrangements , 2010, Nature Genetics.

[12]  J. Isaacs,et al.  DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer. , 2009, Endocrine-related cancer.

[13]  J. Isaacs,et al.  Stabilizing Androgen Receptor in Mitosis Inhibits Prostate Cancer Proliferation , 2007, Cell cycle.

[14]  C. Drake,et al.  Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells , 2006, Proceedings of the National Academy of Sciences.

[15]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Isaacs,et al.  Androgen receptor outwits prostate cancer drugs , 2004, Nature Medicine.

[17]  R L Vessella,et al.  Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .

[18]  J. Trapman,et al.  Androgen-regulated gene expression in prostate cancer. , 1997, Seminars in cancer biology.

[19]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[20]  D. Tindall,et al.  Hormonal regulation of prostate‐specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP , 1992, The Prostate.